Fri, Nov 28, 2014, 1:42 PM EST - U.S. Markets closed early today


% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • one_dogydog one_dogydog Jan 20, 2013 11:01 AM Flag

    FRom 10-Q for VIVUS Inc Nov.2012 The details of ACQLAIM havn't yet agreed with FDA and it cost VVUS $250 million for study.

    We anticipate that our research and development expenses for the remainder of 2012 will increase significantly as compared to 2011 as we continue the planning phase of a post-approval cardiovascular outcomes study for Qsymia, known as ACQLAIM. The details of ACQLAIM have not yet been agreed with the FDA. This study could cost between $200 and $250 million and take as long as five to six years to complete. There are likely to be additional research and development expenses for other post-approval studies related to STENDRA and Qsymia, and for our investigational drug candidates under development. Our research and development expenses may fluctuate from period to period

    Sentiment: Strong Buy

4.19+0.07(+1.70%)1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.